BIAL Announces Oral Presentation at GBA1 Meeting 2025

(identifier: NCT05819359)
For more information about BIAL:?www.bial.com

References:

1.  den?Heijer?JM?et?al. Br J?Clin?Pharmacol. 2021 Sep;87(9):3561-3573; 
2.  Guedes L. et al. Integrated safety analysis of BIA-28-6156 phase 1 clinical trials (a novel allosteric activator of beta-glucocerebrosidase). Presented at the International Congress of Parkinson's Disease and Movement Disorders (MDS), Copenhagen, Denmark. August 27–31, 2023 

Logo - https://mma.prnewswire.com/media/2700080/BIAL_SA_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/bial-announces-oral-presentation-at-gba1-meeting-2025-302469580.html

en | boerse | 67948559 |